ReviewJournal of nanobiotechnology2025
Nanoscale metal-organic frameworks as a versatile platform for synergistic combination tumor therapy.
Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Deep eutectic solvent-enabled green synthesis of gold nanoparticle-decorated ZIF-L composites for colorimetric detection of trimethoprim.Nanoscale advances · 2026Article
- Review
- Illuminating the path to oncolysis: rise of microbial phototherapy.Journal of nanobiotechnology · 2026Review
- Cu-based metal-organic frameworks: synthesis, biomedical applications, and beyond.Discover nano · 2026Review
- A pH-responsive mesoporous Zn-MOF nanocarrier for efficient cisplatin delivery and inhibition of A549 cancer cells.Journal of materials science. Materials in medicine · 2026Article
- Rational Design and Responsive Transdermal Cargo Delivery of Microneedles in the Treatment of Melanoma.International journal of nanomedicine · 2026Review
- Progress in the Development of Metal-Organic Frameworks (MOFs) for Medical Imaging of Tumors: Prospects and Challenges.International journal of nanomedicine · 2026Review
- Therapeutic Potential of Nanoscale Metal-Organic Frameworks in Hepatocellular Carcinoma.Nanomaterials (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
As the second most common cause of death globally, tumor significantly impacts human health and quality of life. Although monotherapy has achieved remarkable progress, its therapeutic effectiveness remains less than ideal. The current strategy is increasingly inclined towards a combination of different treatments. Combination therapy is conducive to rectifying the inherent flaws of monotherapy, surmounting multi-drug resistance, and attaining a synergistic effect. The advancement of nanotechnology offers an unparalleled opportunity for anti-tumor combination therapy. Metal-organic frameworks (MOFs) possess distinctive structural features, including adjustable pore sizes, diverse organic ligands and metal ion centers, as well as the modifiability of functional sites. These characteristics render the combined application of multiple therapeutic approaches feasible. This article provides a review of the research on MOFs-based nano drug delivery platform for anti-tumor combination therapy under physiological conditions or exogenous stimulation. The opportunities and challenges of MOFs entering the clinic for anti-tumor combination therapy are also discussed to provide reference for the further application of MOFs, and provide a novel idea for the research of MOFs-based drug delivery system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.